Status:
COMPLETED
Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate a new questionnaire to capture the patient experience of COPD. The information collected will be used to validate the Shortness of Breath with Daily Activities...
Detailed Description
Dyspnea, referred to by patients as "shortness of breath" or "breathlessness," is frequently associated with decreases in functional status, quality of life, and disabilities. Currently available ques...
Eligibility Criteria
Inclusion
- Adults ≥ 40 years of age
- Established clinical history of COPD by ATS/ERS definition
- Former or current smoker \> 10 pack years
- Evidence of dyspnea
Exclusion
- Has a respiratory disorder other than COPD
- Cancer not in complete clinical remission
- Clinically significant cardiovascular, neurological, psychiatric, renal, gastro-intestinal, immunological, endocrine, or hematological abnormalities that are uncontrolled
Key Trial Info
Start Date :
October 29 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
366 Patients enrolled
Trial Details
Trial ID
NCT00984659
Start Date
October 29 2009
End Date
July 1 2010
Last Update
August 29 2018
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Jasper, Alabama, United States, 35501
2
GSK Investigational Site
Mobile, Alabama, United States, 36608
3
GSK Investigational Site
Los Angeles, California, United States, 90095-1690
4
GSK Investigational Site
Riverside, California, United States, 92506